IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients...
TW's Take: more outstanding data from INAB. The program is expensive but appears to be successful in keeping patients alive.
100% of treated leukemia...
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American...
TW's Take: good data as INAB continues to show efficacy in a very difficult disease.
92% of evaluable patients treated with INB-200 for glioblastoma...
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations...
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024
TW's Take: INAB's programs continue to put forth excellent data, albeit early stage in this case.
- Preclinical data supports potential for proprietary nsCAR platform...
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR...
TW's Take: INAB continues to demonstrate strong science backing their gamma-delta T Cell programs.
New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T...
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in...
TW's Take: nice endorsement of IN8's therapy. No new news in this article, however.
Peer-reviewed publication discusses current strategy and future direction of new...
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable...
TW's Take: Positive data post yesterday's financing is a great set up for INAB.
Durable complete remission (CR) achieved in 100% of treated patients,...
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
TW's Take: solid deal removes the overhang and enables them to get more funding in the future without needing to go to market. Some...
IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
TW's Take: Solid progress with more data expected in December. IN8bio continues to execute but the balance sheet remains an issue and partnering has...
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with...
TW's Take: INAB's programs are showing great early-stage efficacy. Getting a late-breaking poster slot is proof that more, high-quality data is coming from IN8bio.
...
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed...
TW's Take: data on Nov. 17th will likely be compelling. INAB continues to keep patients alive and progression free far longer than expected.
Data...
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the...
TW's Take: while early stage, allogeneic gamma-delta T-cells would be a very big deal. INAB continues to execute on their vision.
This data represents...
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023...
TW's Take: more positive data. INAB is executing and patients continue to do very well on their drugs.
New data on the completed dose-escalation of this...
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta...
TW's Take: Solid progress from INAB in this very promising therapy.
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400...
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
TW's Take: patients continue to see progression-free survival far in excess of expectations. The presentation will continue to highlight this fact. INAB is executing...
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on...
TW's Take: All systems firing for INAB as they look to get more interest in their programs which are doing well despite the share...
IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
TW's Take: positive execution on their business strategy which positions them even better for potential partnering activity.
~ Newly granted patents expand the use of...
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
TW's Take:
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapies
The...
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO...
TW's Take: 100% exceeding PFS with dose response and minimal toxicity is all anyone could ask for from this program. Next up for INAB...
IN8bio’s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
TW's Take: INAB is looking to partner their programs and the strong results in conjunction with TMZ, the standard of care in many cases,...
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th...
TW's Take: More positive data that pulls in another possible avenue for partnering.
Preclinical data demonstrates that gamma-delta T cells have the ability to...
IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to...
TW's Take: obviously good data with an oral presentation, INAB continues to kick butt in all their clinical programs.
NEW YORK, (GLOBE NEWSWIRE) -- IN8bio,...
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T...
TW's Take: simply outstanding data from this program. While the balance sheet remains an issue, the value being created here is substantial and we...
IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program...
TW's Take: more solid progress from INAB. The disconnect between the valuation and the success the science demonstrates continues to grow.
NEW YORK, April 17,...
IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at...
TW's Take: more positive news from INAB which appears to be very successful with all their programs to date.
NEW YORK, April 11, 2023 (GLOBE...
IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual...
TW's Take: yet more very positive data from INAB. As more patients get dosed in trials, this is setting up to be a very...
IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy...
TW's Take: Exciting data that should help drive important partnering conversations for INAB with potential large pharma partners.
NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE)...
IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals
TW's Take: Gamma-Delta T-Cells is a very hot space and IN8bio is proving to be a leader here. The stock is dramatically undervalued relative...
IN8bio to Present at Biotech Showcase 2023 in San Francisco
TW's Take: expecting good news from their GBM program this coming week before they start presenting to investors in San Francisco.
NEW YORK, Jan. 03,...